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A B S T R A C T
We report the generation of the human iPSC line LEIi008-A from a patient with retinitis pigmentosa-11 caused by a dominant nonsense mutation in the PRPF31 gene
(NM_015629.3:c.1205C > A p.(Ser402Ter)). A second line, LEIi009-A, was generated from a related non-penetrant carrier of the same mutation with no retinal disease.
Reprogramming of patient dermal fibroblasts using episomal plasmids containing OCT4, SOX2, KLF4, L-MYC, LIN28, shRNA for p53 and mir302/367 microRNA
generated cell lines displaying pluripotent stem cell marker expression, a normal karyotype and the capability to differentiate into the three germ layer lineages.
Resource table
Unique stem cell lines identifier LEIi008-A
LEIi009-A
Alternative names of stem cell lines 1093ips4 (LEIi008-A)
1374ips1 (LEIi009-A)
Institution Lions Eye Institute, Nedlands, Western Australia, Australia
Contact information of distributor Samuel McLenachan: smclenachan@lei.org.au
Fred Chen: fredchen@lei.org.au
Type of cell lines iPSC
Origin Human
Cell Source Dermal fibroblasts
Clonality Clonal
Method of reprogramming Episomal
Multiline rationale Unaffected mother and affected son carrying same dominant PRPF31 mutation
Gene modification Yes
Type of modification Hereditary
Associated disease Retinitis Pigmentosa 11
Gene/locus PRPF31/19q13.42
Method of modification N/A
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date LEIi008-A: 18/12/17; LEIi009-A: 17/11/17
Cell line repository/bank https://hpscreg.eu/cell-line/LEIi008-A
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Retinitis pigmentosa-11 (RP11) is caused by dominant mutations in
the PRPF31 gene, however up to 30% of PRPF31 mutation carriers are
non-penetrant. The two iPSC lines described here were derived from an
RP11 patient and his unaffected mother and provide a unique oppor-
tunity to examine the non-penetrance of RP11 mutations.
Resource details
RP11 is the most common form of autosomal dominant retinitis
pigmentosa and is caused by dominant mutations in the PRPF31 gene,
which encodes the pre-RNA processing factor-31 protein. Despite the
ubiquitous expression of PRPF31, mutations in this gene specifically
affect the retina, leading to visual impairment and retinal degeneration.
The pathophysiology of RP11 is thought to be driven by PRPF31 hap-
loinsufficiency (Rose and Bhattacharya, 2016), with retinal tissues
preferentially affected due to their high dependence on alternative
splicing (Wilkie et al., 2006). Reduced levels of total PRPF31 transcript
as well as a delayed rate of spliceosome assembly and pre-mRNA pro-
cessing have been reported in RP11 patients (Frio et al., 2008). Inter-
estingly, RP11 displays non-penetrance in affected families, with 30%
of carriers remaining free from retinal disease. The non-penetrance of
PRPF31 mutations has been associated with modifying factors influ-
encing expression of the unaffected PRPF31 allele, such as promoter
elements and transcriptional repressors (Rose and Bhattacharya, 2016).
We identified an Indigenous Australian family affected by RP11.
Affected individuals displayed posterior subcapsular cataract, rod cone
dystrophy and macular cysts with onset of symptoms ranging from 5 to
25 years of age. All affected siblings (n=4) carried the NM_015629.3:c.
1205C > A p.(Ser402Ter) mutation. Dermal fibroblasts were cultured
from skin biopsies taken from an affected RP11 patient and his unaffected
mother, both of whom carried the c.1205C > A mutation in PRPF31. The
presence of the c.1205C > A mutation in each fibroblast line was con-
firmed Sanger sequencing of a PCR product (Fig. 1A). Fibroblasts from
each patient were transfected with episomal plasmids containing OCT4,
SOX2, KLF4, L-MYC, LIN28, shRNA for p53 and mir302/367 microRNA.
After 20–25 days, colonies were picked for clonal expansion. LEIi008-A
iPSC were derived from the affected male patient, while LEIi009-A iPSC
were derived from his unaffected mother (Table 1, Table 2). Both lines
displayed morphology typical of pluripotent stem cell cultures (Fig. 1A).
DNA fingerprinting by short tandem repeat analysis demonstrated each
iPSC line matched its donor fibroblast line at 16 loci (Supplementary Fig.
S1). Expression of the OCT4, NANOG and SOX2 proteins as well as the
pluripotency marker TRA-1-81 was demonstrated in both lines by im-
munocytochemistry (Fig. 1B). Digital karyotyping by genome-wide SNP
profiling and copy number variation analysis demonstrated LEIi008-A nor
LEIi009-A had undergone genomic alterations, with both lines displaying a
normal karyotype (46,XY and 46,XX, respectively, Fig. 1C, Supplementary
Fig. S2). Quantitative RT-PCR demonstrated both LEIi008-A and LEIi009-
A expressed similar levels of pluripotency marker expression to a com-
mercial control human iPSC line (Fig. 1D). PCR screening demonstrated
both lines were negative for mycoplasma and for episomal reprogramming
plasmids (Supplementary Fig. S3). After two weeks of spontaneous dif-
ferentiation, embryoid bodies derived from LEIi008-A and LEIi009-A ex-
pressed markers of ectoderm (PAX6,OTX1), mesoderm (DCN, GATA2) and
endoderm (AFP) (Fig. 1E). To demonstrate the capacity for retinal differ-
entiation, LEIi008-A and LEIi009-A were differentiated as retinal orga-
noids. After 2months, both lines produced retinal organoids containing
pigmented RPE cells. RPE cells were isolated from retinal organoid cul-
tures and cultured as pure monolayers (Fig. 1F, micrographs). After
3weeks of differentiation, quantitative RT-PCR analysis demonstrated
iPSC-RPE from both donors expressed the RPE markers RPE65 and BEST1
and downregulated OCT4 expression (Fig. 1F, graph).
Materials and methods
Cell culture and reprogramming
Patient fibroblasts were cultured in DMEM medium supplemented
with 10% fetal calf serum and antibiotic-antimycotic (ThermoFisher).
Patient iPSCs were cultured in feeder-free conditions, on Geltrex-coated
(ThermoFisher) culture plates in TeSR-E8 medium (StemCell
Technologies). For passaging, iPSC were treated with EDTA Buffer
(1xDPBS without Ca+2 and Mg+2/0.5mM EDTA/30mM NaCl) for 5min
at room temperature. The buffer was then removed and replaced with
TeSR-E8 media. Colonies were then mechanically scraped into the media
and seeded into new Geltrex-coated culture wells at a ratio of 1:3–1:5.
Media changes were performed daily and passaging was performed every
4–5 days. All cultures were maintained in a humidified incubator at 37 °C
with 5% CO2. Patient fibroblasts were reprogrammed using the Episomal
iPSC Reprogramming Plasmid kit (SC900A-1, System Biosciences), ac-
cording to the manufacturer's instructions. Colonies were picked for
clonal expansion on days 21–25. PCR screening for episomal plasmids
was performed at passage 9 for LEIi008-A and passage 10 for LEIi009-A,
with fibroblasts transfected with reprogramming episomes and early
passage iPSC used as positive controls. PCR was performed using SYBR
PCR Master Mix (QIAGEN) and 200 nM of each primer. The reactions
were performed on the CFX Connect Real-Time PCR Detection System
(Biorad) using the following cycling conditions: 95 °C for 5 s, then
30 cycles of 95 °C for 10s and 60 °C for 15 s. Mycoplasma testing was
performed using the Lookout Mycoplasma PCR Detection Kit (Sigma-
Aldrich) according to the manufacturer's instructions. A commercial iPSC
line (ThermoFisher, Cat#A18945, HuiPSC) was used as a control.
iPSC differentiation
For trilineage differentiation, iPSCs were cultured as embryoid bodies
(EBs). IPSC were treated with EDTA Buffer for 5min at room tempera-
ture, the buffer was then removed and replaced with TeSR-E8 media
containing 10 μM Y27632 (Abcam). Colonies were mechanically scraped
into the media, and then seeded into Greiner suspension culture 6 well
plates in TeSR-E8 media supplemented with 10 μM Y27632. On day 3,
the media was changed to DMEM/F12 supplemented with 20% knockout
serum replacement (KSR), Minimal Essential Media Non-Essential Amino
Acids Solution (NEAA) and antibiotic-antimycotic (ThermoFisher).
Media was changed every second day. On day 14, EBs were collected for
qPCR analysis. Trilineage differentiation was assessed by the induction of
genes for ectoderm (PAX6, OTX1) endoderm (AFP) and mesoderm (DCN,
GATA2). For directed differentiation into retinal organoids we followed a
previously published protocol (Mellough et al., 2012). After 2months of
differentiation, organoids containing pigmented RPE were collected and
treated with TrypLE™ Express Enzyme (ThermoFisher) for 10min at
37 °C. The RPE cells were seeded into Geltrex-coated wells of a 24 well
plate in RPE media (DMEM/F12, NEAA, B27, N2, 10 ng/ml IGF-1, 4%
KSR and antibiotic-antimycotic).
qPCR analysis
Total mRNA was isolated using TRIzol Reagent (ThermoFisher) and
cDNA was synthesized using the RT2 First Strand Kit (Qiagen). qPCR re-
actions were prepared using RT2 SYBR Green qPCR Mastermixes (Qiagen),
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and performed using the CFX Connect Real-Time System (BioRad). Data
was analyzed using the ΔΔCT method. Gene expression values were nor-
malized to GAPDH expression. Primers used are listed in Table 3.
Immunostaining analysis
Cells were fixed with 4% paraformaldehyde for 15min at 37 °C, wa-
shed, then permeabilized using phosphate buffered saline (PBS) with 0.3%
Triton X-100 for 15min. The cells were then incubated in blocking buffer
(5% normal goat serum with 0.3% Triton X-100 (Sigma-Aldrich) in PBS)
for 1 h at room temperature. Primary antibodies were diluted in blocking
buffer and applied at 4 °C overnight. Secondary antibodies were applied
for 2 h at room temperature. Nuclei were stained with DAPI. Antibodies
used are listed in Table 3. Cells were examined using the Olympus BX60
fluorescence microscope and imaged using Olympus DP-Controller
3.1.1.267 acquisition software (Olympus Corporation, Tokyo, Japan).
Digital karyotyping
Digital karyotyping was performed on LEIi008-A (passage 4) and
LEIi009-A (passage 10) iPSC using the Illumina HumanCoreExome-24
Beadchip SNP array (D'Antonio et al., 2017). DNA was isolated using
the FlexiGene DNA kit (QIAGEN). CNV analysis was performed on
GenomeStudio 2.0 software using the CNVpartition 2.0 plugin (Illu-
mina). To identify genomic alterations (deletions or duplications over
500 kb), B allele frequencies (Fig. 1C), LogR ratios and CNV values were
Fig. 1. A: Sanger sequencing of the PRPF31 gene demonstrated the presence of the c.1205C>A mutation in the parental fibroblasts used to generate the LEIi009-A
and LEIi009-A iPSC lines (chromatograms). Both LEIi008-A and LEIi009-A displayed morphologies typical of pluripotent stem cell colonies (images). B: The ex-
pression of pluripotency markers (OCT4, NANOG, SOX2 and TRA-1-81) in LEIi008-A and LEIi009-A was demonstrated by immunocytochemistry. Nuclei were
counterstained with DAPI (merged images). C: Digital karyotyping of LEIi008-A and LEIi009-A was performed using the Illumina HumanCoreExome-24 Beadchip
SNP array. B-allele frequencies were plotted against genomic location for 500,000 human SNPs, demonstrating normal, 46,XY and 46,XX karyotypes in each line
respectively. D: Quantitative RT-PCR demonstrated similar levels of expression of pluripotency genes (OCT4, NANOG, and KLF4) in LEIi008-A (grey bars) and
LEIi009-A (dark grey bars) and a commercial human iPSC line (white bars). Relative expression values were normalised to GAPDH expression using the ΔCt method.
Error bars indicate standard deviation. E: Expression of ectodermal (PAX6, OTX1), mesodermal (DCN, GATA2) and endodermal (AFP) genes was increased in
embryoid bodies (black bars) derived from LEIi008-A (left graph) and LEIi009-A (right graph), compared with undifferentiated iPSC (grey bars). Relative expression
values were normalised to GAPDH expression using the ΔCt method. Error bars indicate standard deviation. F: Monolayers of RPE cells could be derived from
LEIi008-A (left image) and LEIi009-A (right image) iPSC. Quantitative PCR analysis demonstrated expression of the RPE markers RPE65 and BEST1 was upregulated
in RPE derived from both patient iPSC lines, while expression of OCT4 was downregulated. Expression values were calculated using the ΔΔCt method, normalised to
GAPDH and expressed as fold changes compared with undifferentiated iPSC. Error bars indicate standard deviation.
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
LEIi008-A 1093IPSC_4P4 Male 28 Indigenous Australian PRPF31 RP11
c.1205C > A




Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis: Immunocytochemistry Positive staining for pluripotency markers: OCT4,
NANOG, SOX2, TRA-1-81
Fig. 1 panel B
Quantitative analysis: RT-qPCR Expression of OCT4, NANOG and KLF4 Fig. 1 panel D
Genotype Digital Karyotyping by Illumina SNP
Beadchip and CNV analysis
LEIi008-A: 46, XY Fig. 1 panel C, Supplementary Fig. S2
LEIi009-A: 46, XX
Resolution: 500 kB
Identity STR analysis LEIi008-A: Matched at 16 loci Supplementary Fig. S1 Raw data
available with the authorsLEIi009-A: Matched at 16 loci
Mutation analysis (IF
APPLICABLE)
Sequencing LEIi008-A PRPF31 c.1205C > A (Heterozygous) Fig. 1 panel A
LEIi009-A: PRPF31 c.1205C > A (Heterozygous)
Microbiology and virology Mycoplasma Mycoplasma testing by PCR: Negative Supplementary Fig. S3B
Differentiation potential Embryoid body formation Induction of ectoderm (PAX6, OTX1), mesoderm (DCN,
GATA2) and endoderm (AFP, SOX7) marker gene
expression
Fig. 1 panel E
Directed differentiation to retinal organoids Induction of pigmented RPE cells expressing RPE65 and
BEST1
Fig. 1 panel F
Donor screening (Optional) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(Optional)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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plotted against genomic location (Supplementary Fig. S2). This method
does not reveal copy number neutral changes such as balanced trans-
locations.
Microsatellite analysis
Analysis of microsatellites was performed using the PowerPlex
16HS system (Promega, performed at the Australian Genome Research
Facility). Patient fibroblasts (1093-FB, 1374-FB), LEIi008-A and
LEIi009-A were genotyped at the loci D18S51, D21S11, TH01,
D3S1358, Penta E, FGA, TPOX, D8S1179, vWA, CSF1PO, D16S539,
D7S820, D13S317, D5S818, Penta D and Amelogenin (Supplementary
Fig. S1). Results are shown as a heatmap, demonstrating matching
genotypes at all loci examined.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.11.018.
References
D'Antonio, M., Woodruff, G., Nathanson, J.L., D'Antonio-Chronowska, A., Arias, A.,
Matsui, H., Williams, R., Herrera, C., Reyna, S.M., Yeo, G.W., Goldstein, L.S.B.,
Panopoulos, A.D., Frazer, K.A., 2017. High-throughput and cost-effective character-
ization of induced pluripotent stem cells. Stem Cell Rep. 8, 1101–1111.
Frio, T. Rio, Wade, N.M., Ransijn, A., Berson, E.L., Beckmann, J.S., Rivolta, C., 2008.
Premature termination codons in PRPF31 cause retinitis pigmentosa via hap-
loinsufficiency due to nonsense-mediated mRNA decay. J. Clin. Invest. 118,
1519–1531.
Mellough, C.B., Sernagor, E., Moreno-Gimeno, I., Steel, D.H., Lako, M., 2012. Efficient
stage-specific differentiation of human pluripotent stem cells toward retinal photo-
receptor cells. Stem Cells (Dayton, Ohio) 30, 673–686.
Rose, A.M., Bhattacharya, S.S., 2016. Variant haploinsufficiency and phenotypic non-
penetrance in PRPF31-associated retinitis pigmentosa. Clin. Genet. 90, 118–126.
Wilkie, S.E., Morris, K.J., Bhattacharya, S.S., Warren, M.J., Hunt, D.M., 2006. A study of
the nuclear trafficking of the splicing factor protein PRPF31 linked to autosomal
dominant retinitis pigmentosa (ADRP). Biochim. Biophys. Acta 1762, 304–311.
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-OCT4 1:200 StemCell Technologies Cat# 60093, RRID: AB_2561766
Rabbit anti-NANOG 1:100 Abcam Cat# ab21624, RRID: AB_446437
Rabbit anti-SOX2 1:200 Thermo Fisher Scientific Cat# 48–1400, RRID:AB_2533841
Mouse anti-TRA-1-81-AlexaFluor 488 1:100 Stem Cell Technologies Cat# 60065 AD, RRID: AB_1089240
Secondary antibodies Alexa Fluor 546 Goat Anti-Mouse IgG 1:500 Molecular Probes Cat# A-11003, RRID: AB_141370
Alexa Fluor 488 Goat Anti-Rabbit IgG 1:500 Molecular Probes Cat# A-11008, RRID: AB_143165
Primers
Target Forward/Reverse primer (5′-3′)
Episomal plasmid detection Reprogramming Plasmids (95 bp product) AGGTCCCTCGAAGAGGTTCA/TTCCAACGCGAGAAGGTGTT
Pluripotency markers (qPCR) OCT4 CCTGAAGCAGAAGAGGATCACC/AAAGCGGCAGATGGTCGTTTGG
NANOG CTCCAACATCCTGAACCTCAGC/CGTCACACCATTGCTATTCTTCG
KLF4 CATCTCAAGGCACACCTGCGAA/TCGGTCGCATTTTTGGCACTGG
House-keeping genes (qPCR) GAPDH GTCTCCTCTGACTTCAACAGCG/ACCACCCTGTTGCTGTAGCCAA





Mutation sequencing PRPF31 Intron 11-Intron 12 ACTCTGAGCTCACAGAGCAG/GCCATATACGACGCTCTGCT
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